CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Ahn, M-J [1 ]
Crino, L. [2 ]
Solomon, Ben [3 ]
Zhou, Caicun [4 ]
Ou, Sai-hong I. [5 ]
Selaru, P. [6 ]
Cohen, D. P. [6 ]
Bartlett, C. H. [7 ]
Kim, Dong-wan [8 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Osped S Maria Misericordia, Perugia, Italy
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
[4] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[5] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Med Hematol Oncol, Orange, CA 92668 USA
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, New York, NY USA
[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
poor performance status; brain metastases; elderly; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-036
引用
收藏
页码：S490 / S491
页数：2
相关论文
共 50 条
  • [41] Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Hu, Limei
    Xie, Youjun
    Zhao, Hongying
    PULMONOLOGY, 2024, 30 (04): : 406 - 407
  • [42] Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Santini, Fernando
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Litvak, Anya
    Jones, David Randolph
    Kris, Mark G.
    Shaw, Alice Tsang
    Gainor, Justin F.
    Chaft, Jamie E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [44] Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema
    Van Damme, Eufra
    Kiselinova, Maja
    Van Schoote, Elke
    TUMORI JOURNAL, 2019, 105 (06): : NP35 - NP37
  • [45] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [46] Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Shaw, Alice T.
    Martini, Jean-Francois
    Besse, Benjamin
    Bauer, Todd M.
    Lin, Chia-Chi
    Soo, Ross A.
    Riely, Gregory J.
    Ou, Sai-Hong Ignatius
    Clancy, Jill S.
    Li, Sherry
    Thurm, Holger
    Satouchi, Miyako
    Camidge, D. Ross
    Kao, Steven
    Chiari, Rita
    Gadgeel, Shirish
    Felip, Enriqueta
    Solomon, Benjamin J.
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Evaluation of Texture Analysis Parameters in EGFR Mutated or ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
    Bluthgen, Maria V.
    Caramella, Caroline
    Rosellini, Silvia
    Leduc, Charlotte
    Facchinetti, Francesco
    Haspinger, Eva
    Ferte, Charles
    Michiels, Stefan
    Soria, Jean C.
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S703 - S703
  • [48] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer
    Wilner, Keith D.
    Usari, Tiziana
    Polli, Anna
    Kim, Elizabeth E.
    FUTURE ONCOLOGY, 2019, 15 (10) : 1097 - 1103
  • [50] Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Vizcarrondo, F. R.
    Patel, S. P.
    Pennell, N. A.
    Pakkala, S.
    West, H.
    Kratzke, R.
    Tarazi, J.
    Wilner, K.
    Polli, A.
    Tan, W.
    Liu, Y.
    Valota, O.
    Piperdi, B.
    Reckamp, K. L.
    ANNALS OF ONCOLOGY, 2016, 27
12345